Maria Berkman

Relief Cardiovascular, an inQB8 Medical Technologies portfolio company, is creating a novel smart implant to decongest heart failure patients. The Relief System is the world’s first transcatheter implant to both monitor and modulate renal vein pressures, offering a novel solution for managing fluid in heart failure patients – particularly for the millions of heart failure patients with diuretic resistance.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.

Alleviant Medical is a medical device company developing potential therapies for congestive heart failure.

FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion. FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families. FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi , M Capital, NACO, UI Investment, & Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions. FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the hearts natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.

Apama Medical is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical device incubator. We were founded to provide innovative solutions that address unmet clinical needs in the underpenetrated and rapidly growing atrial fibrillation (AF) market. We have gathered leaders in the medical device industry to lead Apama in developing next generation AF ablation technology. Our team has proven industry experience and shares a passion for developing technologies that improve patients’ lives. Our novel ablation catheter is the only product that combines the best elements of existing ablation technology, while incorporating additional unique features to address unmet market needs. Our system improves procedural efficiency via a multipoint, single shot design that allows for reduced procedure times and more versatile ablation capabilities. As a result, our technology can address various types of AF patients through its ability to create customizable ablation geometries. In addition, our ablation catheter has built-in cameras that provide optimal feedback on ablation quality via real-time visualization, and has incorporated irrigation to ensure patient safety. Our catheter also integrates mapping and pacing to streamline the procedure and to reduce additional procedure costs. Learn more at apamamedical.com

Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillation therapy using low-electrical energy designed to more gently restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.

Vascular Graft Solutions (VGS), was founded in 2009 and is focusing on the development and commercialization of innovative solutions to improve the outcome of bypass surgeries. The company’s leading product, the VEST (Venous External Scaffolding Technology), is a novel external mechanical support for autologous vein grafts, intended for improving vein graft longevity. Pre-clinical and clinical studies confirmed that by restraining wall tension and improving lumen uniformity, the VEST optimizes vein graft hemodynamics and mitigates vein graft disease. Randomized controlled trials and real-world data studies in Europe, demonstrated the biomechanical effect of external stenting, its statistically significant mitigation of vein graft disease, and improved clinical outcomes.

Vensana Capital is a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Launched in 2019 by Kirk Nielsen and Justin Klein, Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services.

Relief Cardiovascular, an inQB8 Medical Technologies portfolio company, is creating a novel smart implant to decongest heart failure patients. The Relief System is the world’s first transcatheter implant to both monitor and modulate renal vein pressures, offering a novel solution for managing fluid in heart failure patients – particularly for the millions of heart failure patients with diuretic resistance.

In 2018, the Leducq Trust launched Longview Ventures to make investments in select portfolio companies of Broadview Ventures, a mission-driven investment organization focused on cardiovascular disease and stroke. Longview focuses on clinical-stage companies, Series B – Series C, as a complement to Broadview’s continued dedication to Seed and Series A financings.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.

Alleviant Medical is a medical device company developing potential therapies for congestive heart failure.